SEC Form 4 · accession 0001193125-26-294528
Relay Therapeutics, Inc. · RLAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Rahmer
Officer — See remarks
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:12 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001812364
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jun 30, 2026 | S | 50,000 | $19.09 | D | 225,857 | D | |
| Common StockF5,F3 | Jun 30, 2026 | A | 3,056 | $6.95 | A | 228,913 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2025.
- F2This transaction was executed in multiple trades at prices ranging from $18.66 to $19.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3Includes 9,153 shares underlying restricted stock units.
- F4The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
- F5In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on January 2, 2026.
Remarks
Chief Corporate Development Officer